Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 341.00K | 457.00K | 206.00K | 238.00K | 137.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 341.00K | 457.00K | 206.00K | 238.00K | 137.00K |
| Cost of Revenue | 512.00K | 26.00K | 9.00K | 9.00K | 11.00K |
| Gross Profit | -171.00K | 431.00K | 197.00K | 229.00K | 126.00K |
| SG&A Expenses | 24.34M | 25.87M | 23.60M | 20.76M | 17.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.48M | 52.87M | 51.40M | 53.13M | 39.13M |
| Operating Income | -44.13M | -52.41M | -51.20M | -52.89M | -38.99M |
| Income Before Tax | -50.49M | -53.52M | -52.80M | -54.81M | -41.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.49M | -53.52M | -52.80M | -54.81M | -41.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.49M | -53.52M | -52.80M | -54.81M | -41.81M |
| EBIT | -44.13M | -52.41M | -51.20M | -52.89M | -38.99M |
| EBITDA | -44.06M | -52.33M | -51.12M | -52.81M | -38.91M |
| EPS Basic | -1.73 | -1.83 | -1.85 | -1.95 | -1.49 |
| Normalized Basic EPS | -0.99 | -1.15 | -1.15 | -1.22 | -0.93 |
| EPS Diluted | -1.73 | -1.83 | -1.85 | -1.95 | -1.49 |
| Normalized Diluted EPS | -0.99 | -1.15 | -1.15 | -1.22 | -0.93 |
| Average Basic Shares Outstanding | 29.27M | 29.19M | 28.62M | 28.07M | 28.02M |
| Average Diluted Shares Outstanding | 29.27M | 29.19M | 28.62M | 28.07M | 28.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |